1. Home
  2. LARK vs MOLN Comparison

LARK vs MOLN Comparison

Compare LARK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

N/A

Current Price

$28.24

Market Cap

167.8M

Sector

Finance

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.96

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LARK
MOLN
Founded
1885
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LARK
MOLN
Price
$28.24
$3.96
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
9.0K
3.5K
Earning Date
02-03-2026
10-30-2025
Dividend Yield
2.78%
N/A
EPS Growth
38.73
N/A
EPS
2.84
N/A
Revenue
$64,367,999.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,000.00
P/E Ratio
$10.12
N/A
Revenue Growth
12.95
N/A
52 Week Low
$20.99
$3.36
52 Week High
$29.56
$5.91

Technical Indicators

Market Signals
Indicator
LARK
MOLN
Relative Strength Index (RSI) 59.69 49.42
Support Level $28.00 $3.92
Resistance Level $28.98 $4.35
Average True Range (ATR) 0.83 0.18
MACD 0.01 -0.03
Stochastic Oscillator 44.29 36.96

Price Performance

Historical Comparison
LARK
MOLN

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: